HR Execs on the Move

Syros

www.syros.com

 
Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, the Company’s gene control platform has broad potential to achieve profound and durable benefit across a range of diseases. Syros is focused on cancer and immune-mediated diseases and ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.syros.com
  • 620 Memorial Drive Suite 300
    Cambridge, MA USA 02139
  • Phone: 617.744.1340

Executives

Name Title Contact Details
Conley Chee
 Chief Commercial Officer Profile
Jaimie Mailander
 Associate Director, Human Resources Profile
Harriet Winter
 Vice President, Global Product Leadership Profile
Jason Haas
 Chief Financial Officer Profile
Lisa Roberts
 Director Human Resources Profile

Similar Companies

Sisters of Saint Joseph of Philadelphia

We are a community of approximately 825 women religious. Originally founded in 1650 in LePuy, France, the Sisters of Saint Joseph came to Philadelphia in 1847. Through our many ministries, including educations, healthcare, social services and parish m...

VistaGen

VistaGen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. VistaGen`s clinical-stage candidates are targeting multiple forms of anxiety and depression. They belong to a new class of drugs known as pherines, which are odorless, tasteless, neuroactive steroids that bind to distinct receptors on chemosensory neurons in the nasal passages and can impact the limbic amygdala without systemic uptake or direct activity on CNS neurons in the brain. VistaGen`s lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the U.S., with results anticipated in 2022. Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder. With an experienced leadership team, VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression.

SST Corporation

SST Corporation is a Clifton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Encore Dermatology

Headquartered in Malvern, Pennsylvania, Encore Dermatology is a privately held fully integrated dermatology company with a mission committed to delivering innovative prescription therapies and medical devices to dermatologists focusing on customer service and improving the quality-of-life of patients.

Transtracheal Systems Inc

Transtracheal Systems Inc is a Englewood, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.